Scisparc-clearmind collaboration leads to publication of patent for binge behaviour combination treatment in mexico

Tel aviv, israel, feb. 04, 2025 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with clearmind medicine inc. (“clearmind”) (nasdaq: cmnd) (fse: cwy), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, clearmind has announced the publication of a patent application in mexico for the innovative combination of 3,4-methylenedioxymethamphetamine (mdma) with n-acylethanolamines.
SPRC Ratings Summary
SPRC Quant Ranking